Alkem Laboratories Launches NeuCeno for Adult Partial-Onset Seizure Treatment in India

Market snapshot: Alkem Laboratories has announced the landmark launch of NeuCeno (cenobamate), a novel anti-seizure medication for adults with partial-onset seizures. Marking the first time this advanced therapeutic option is available in India, NeuCeno provides once-daily oral dosing options across six tablet strengths. This launch addresses a critical healthcare gap in India, where an estimated 9.4 million people live with epilepsy.

Data Snapshot

• Clinical trials show up to a 78% reduction in seizure frequency among adult patients using adjunctive cenobamate.
• Up to 30% of adult patients achieved complete seizure freedom during the maintenance phase of clinical trials.
• The domestic addressable market comprises an estimated 9.4 million people living with epilepsy in India.
• The drug is offered in six distinct once-daily oral tablet strengths: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.

What's Changed

• Alkem Laboratories introduced cenobamate (NeuCeno) to the Indian market for the first time, expanding its neuropsychiatry presence.
• Consolidated revenue from operations for Q1 FY27 increased 10.95% YoY to ₹3,740.15 crore from ₹3,371.14 crore in Q1 FY26.
• Consolidated net profit for Q1 FY27 decreased 21.21% YoY to ₹520 crore from ₹660 crore in Q1 FY26 due to higher tax expenses.
• Alkem Medtech Private Limited acquired a 51% to 55% stake in medical device company Occlutech Holding AG in July 2026.

Key Takeaways

• First-in-India Launch: Alkem introduces NeuCeno (cenobamate), offering a new therapeutic option for adult epilepsy management.
• High Clinical Efficacy: Trials show up to 78% reduction in seizure frequency and up to 30% of patients achieving complete seizure freedom.
• Strategic Chronic Focus: The launch aligns with Alkem's efforts to grow its chronic therapy portfolio, such as neurology, which commands better margins.
• Unlocking a Large Market: Directly addresses the treatment needs of India's estimated 9.4 million epilepsy sufferers.

SAHI Perspective

Alkem's launch of NeuCeno is a highly strategic move into the domestic chronic therapy space, specifically neurology. Historically recognized for its leadership in acute therapies like anti-infectives, Alkem's pivot toward chronic drugs is vital for structural margin expansion. While Q1 FY27 consolidated margins remained stable at 20.5% despite high tax outlays, expanding high-barrier chronic treatments like NeuCeno will help the company build stable, recurring revenue lines and protect its domestic formulation outperformance.

Market Implications

The addition of an advanced, first-in-market molecule like NeuCeno enhances Alkem's competitive positioning in the Indian Pharmaceutical Market (IPM). By capturing share in the chronic neurological space, Alkem can drive domestic prescription growth and sustain its double-digit domestic formulations growth rate, which stood at 10.3% YoY in Q1 FY27.

Trading Signals

Market Bias: Bullish

NeuCeno's launch strengthens Alkem's high-margin chronic formulations business, targeting a massive addressable base of 9.4 million epilepsy patients in India. This portfolio enhancement supports long-term structural margin growth, complementing the company's steady 10.95% YoY revenue growth in Q1 FY27.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Adoption rate of NeuCeno among domestic neurologists and patient clinics.
• Regulatory resolution of US FDA OAI status at the Daman formulation plant.
• Sustained domestic formulation growth outperformance compared to the broader Indian Pharmaceutical Market.

Time Horizon: Medium-term (3-12 months)

Industry Context

Epilepsy is a massive neurological health burden in India. Despite multiple existing anti-seizure medications, a high percentage of patients fail to achieve adequate control over focal seizures. The introduction of cenobamate, which has clinical validation showing up to a 78% reduction in seizure frequency, introduces a potent alternative to the market, accelerating the shift toward modern, multi-mechanism chronic therapies.

Key Risks to Watch

• Competitive entry or price controls on neuropsychiatry medications in the domestic market.
• Regulatory overhang from the US FDA OAI classification on the Daman formulation plant.
• High operational opex associated with scaling new business divisions such as medtech and biotech.

Recent Developments

In Q1 FY27, Alkem reported a 10.95% YoY revenue expansion to ₹3,740.15 crore, while net profit dipped 21.21% YoY to ₹520 crore due to a sharp tax expense hike. Furthermore, Alkem's wholly owned subsidiary, Alkem Medtech, acquired a 51% to 55% stake in medical device manufacturer Occlutech Holding AG in July 2026. The company also appointed Dr. Shubhadeep Sinha as a senior management official on September 15, 2026, leveraging his 25 years of pharmaceutical expertise.

Closing Insight

Alkem Laboratories continues to successfully pivot its business mix toward high-margin chronic segments. The introduction of NeuCeno highlights Alkem's commitment to commercializing innovative therapies, which will serve as a key pillar for sustaining its domestic leadership and mitigating near-term bottom-line pressures.

High Performance Trading with SAHI.